SSR2 and hepatocellular carcinoma: Overall, no significant differences were noted when comparing the expression of UPR markers between sexes in HCC patients, with the exception of the markers EIF2S3, SSR2, and ATF4, where a higher expression was observed in female patients (Figure 6A,B).